Claims

1. A composition comprising at least one bacterial strain comprising bile acid deconjugation activity and/or 7-epimerization activity, for use in a method of treating or reducing the risk of intrahepatic cholestasis in a subject, wherein said intrahepatic cholestasis comprises intrahepatic cholestasis of pregnancy, and wherein:

(i) the at least one bacterial strain comprises bile acid deconjugation activity and 7-epimerization activity;

(ii) the at least one bacterial strain comprises at least two bacterial strains, the at least two bacterial strains comprising

(a) a first bacterial strain comprising bile acid deconjugation activity, and

(b) a second bacterial strain comprising 7-epimerization activity; or

(iii) the at least one bacterial strain comprises at least three bacterial strains, the at least three bacterial strains comprising

(c) a first bacterial strain comprising bile acid deconjugation activity,

(d) a second bacterial strain comprising 7α-hydroxysteroid dehydrogenase (HSDH) activity, and

(e) a third bacterial strain comprising 7β-HSDH activity.

2. The composition for use of claim 1, wherein:

the first bacterial strain recited in part (ii) is *Bifidobacterium*, preferably *Bifidobacterium longum*;

the second bacterial strain recited in part (ii) is *Clostridium*, preferably *Clostridium baratii*;

the first bacterial strain recited in part (iii) is *Bifidobacterium*, preferably *Bifidobacterium longum*;

the second bacterial strain recited in part (iii) is *Bacteroides*, preferably *Bacteroides fragilis* and/or *Bacteroides thetaiotaomicron*; and/or

the third bacterial strain recited in part (iii) is *Collinsella*, preferably *Collinsella aerofaciens*.

3. The composition for use of claim 1 or claim 2, wherein the composition further comprises at least one bacterial strain comprising sulfate reducing activity, preferably wherein the bacterial strain comprising sulfate reducing activity is *Desulfovibrio*, more preferably *Desulfovibrio piger*, more preferably *Desulfovibrio piger* DSM 32187.

4. The composition for use of any one of claims 1 to 3,

wherein the composition comprises *Bifidobacterium longum*, *Bacteroides fragilis*, and *Collinsella aerofaciens*; or

wherein the composition comprises *Bifidobacterium longum*, *Bacteroides thetaiotaomicron*, and *Collinsella aerofaciens*; or

wherein the composition comprises *Bifidobacterium longum*, and *Clostridium baratii*; or

wherein the composition comprises *Bifidobacterium longum*, *Bacteroides fragilis*, *Collinsella aerofaciens*, and *Desulfovibrio piger* DSM 32187; or

wherein the composition comprises *Bifidobacterium longum*, *Bacteroides thetaiotaomicron*, *Collinsella aerofaciens* and *Desulfovibrio piger* DSM 32187; or

wherein the composition comprises *Bifidobacterium longum*, *Clostridium baratii* and *Desulfovibrio piger* DSM 32187.

5. The composition for use of any one of claims 1 to 4, wherein said use further comprises a prebiotic.

6. The composition for use of claim 5, wherein the prebiotic is inulin.

7. The composition for use of any one of claims 1 to 6, wherein the subject is a mammal, preferably the subject is a human.

8. The composition for use of any one of claims 1 to 7, wherein said use comprises treating or reducing the risk of pruritis in the subject.